Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals International, plc (KNSA) is a clinical and commercial-stage biopharmaceutical company pioneering immune-modulating therapies for autoimmune and cardiovascular diseases. This dedicated news hub provides investors, researchers, and healthcare professionals with timely updates on corporate developments and scientific advancements.
Access the most comprehensive collection of Kiniksa news including regulatory milestones, clinical trial results, and strategic partnerships. Our curated feed delivers essential updates on ARCALYST commercialization progress, abiprubart development phases, and pipeline expansion efforts – all critical for informed decision-making in biopharma investing.
Key content categories cover FDA submissions, research collaborations, financial performance, and therapy access initiatives. The centralized format ensures efficient tracking of Kiniksa's progress in addressing complex inflammatory conditions through targeted immune modulation.
Bookmark this page for streamlined monitoring of KNSA's evolving position in autoimmune therapeutics. Verify information accuracy through direct links to official company communications and peer-reviewed clinical data sources.
Kiniksa Pharmaceuticals International (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, October 29, 2024, at 8:30 a.m. Eastern Time to report its third quarter 2024 financial results and recent portfolio execution. The live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com.
Individuals interested in participating via telephone can register online to receive dial-in information. A replay of the event will be available on Kiniksa's website within approximately 48 hours after the event.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has partnered with NHL Hall-of-Famer Henrik Lundqvist to launch the Life DisRPted campaign, focusing on raising awareness of recurrent pericarditis. This national initiative aims to promote early diagnosis and treatment of this painful, debilitating chronic autoinflammatory disease.
Lundqvist, diagnosed with recurrent pericarditis in 2021, shares his personal journey in a video titled 'Comeback After Comeback'. The campaign website, LifeDisRPted.com, features this video along with a downloadable Doctor Discussion Guide to help patients communicate with healthcare providers.
Dr. Antonio Abbate, Professor of Cardiology at The University of Virginia, emphasizes the importance of early diagnosis and proactive collaboration with healthcare providers in managing recurrent pericarditis. The campaign seeks to support patients, reduce feelings of isolation, and encourage self-advocacy in disease management.
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced its participation in the 2024 Wells Fargo Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, September 4, 2024, at 8:00 a.m. Eastern Time. Investors and interested parties can access a live webcast of Kiniksa's presentation through the Investors & Media section of the company's official website at www.kiniksa.com. For those unable to attend the live event, a replay will be made available on Kiniksa's website within approximately 48 hours after the presentation concludes.
Kiniksa Pharmaceuticals reported strong Q2 2024 financial results, with ARCALYST net product revenue of $103.4 million, representing 90% year-over-year growth. The company increased its 2024 ARCALYST revenue guidance to $405-$415 million. Key highlights include:
1. Approximately 11% of the 14,000 multiple-recurrence target population actively on ARCALYST treatment.
2. Average total duration of ARCALYST therapy increased to ~26 months.
3. Enrollment began in the abiprubart Phase 2b trial for Sjögren's Disease.
4. Total revenue for Q2 2024 was $108.6 million.
5. Net loss for Q2 2024 was $3.9 million.
6. Cash position of $218.8 million with no debt as of June 30, 2024.
Kiniksa expects to remain cash flow positive on an annual basis, with abiprubart's clinical development fully funded in the current operating plan.
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, July 23, 2024, at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio execution. The event will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Interested individuals can register for telephone participation, and upon registration, will receive confirmation details including a unique passcode and registrant ID. A replay of the event will be available on Kiniksa's website within approximately 48 hours after the event.
Kiniksa Pharmaceuticals has begun enrolling patients in a Phase 2b clinical trial for abiprubart, a humanized anti-CD40 monoclonal antibody, aimed at treating Sjögren’s Disease, a debilitating autoimmune disorder. The trial will assess the efficacy of abiprubart administered biweekly and monthly via subcutaneous injections over a 24-week period, involving around 201 participants. The primary measure of success is the change in the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) compared to a placebo. The study will also include a long-term extension phase where all participants receive active treatment. Importantly, Kiniksa expects to remain cash flow positive during this development.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced a partnership with NHL Hall-of-Famer Henrik Lundqvist to raise awareness about recurrent pericarditis. This campaign, starting in September, aims to share experiences from the recurrent pericarditis community and provide resources for patients and caregivers. Recurrent pericarditis is characterized by severe inflammation of the pericardial tissue, leading to sharp chest pain often mistaken for a heart attack. The disease significantly impacts patients' quality of life and physical wellbeing. CEO Sanj K. Patel emphasized the need for increased disease understanding to prevent delayed diagnosis and treatment. More information can be found at whatispericarditis.com and arcalyst.com.
Kiniksa Pharmaceuticals announced its sponsorship of the American Heart Association's Addressing Recurrent Pericarditis initiative on June 17, 2024. This initiative aims to enhance care for recurrent pericarditis patients through improved diagnosis and treatment practices. The program will involve healthcare champions at 15 sites to identify gaps and share best practices nationwide. The initiative aims to improve patient outcomes and quality of life through education, model sharing, and collaborative research. Key sites involved include Brigham & Women’s Hospital, Cleveland Clinic, and Mayo Clinic.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced its management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled for Tuesday, June 11, 2024, at 8:40 a.m. Eastern Time.
The presentation will be live-streamed on Kiniksa's website under the Investors & Media section. A replay will be available approximately 48 hours post-event.
Kiniksa Pharmaceuticals, (Nasdaq: KNSA) will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on May 14, 2024. The presentation will be available via webcast on the company's website.
